Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).


CSE:RVV - Post by User

Comment by 1ottrunneron Jul 15, 2021 2:23pm
107 Views
Post# 33553235

RE:Back in action !

RE:Back in action !So yes to fireworks or back into the closet until next time?

It was fun for 45 minutes or so wasn't it?

You have to wonder if MF thought this Press was going to be well recieved? 

How about this for a Press release:

Revive Therapeutics today has been informed the DSMB has decided on a single dose vs a placebo for the remainder of the trial.  This decision to continue the trial with refined dosing comes at a time when Covid rates climb throughout the world.  Current vaccinations protocols appear to be limiting the virus syptoms to Mild - Moderate, which buccilamine is a hopefuly candidate for treatment.  RVV expects to be provided with data from the DSMB during Q3/4 and approach the FDA for EUA.  RVV now has a total of 41 recruitment sites and forecasts the by invitation recruitment will be expeditiously completed.


cool888 wrote: Great times ahead !


<< Previous
Bullboard Posts
Next >>